Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Haese

Showing results (61-70 of 214) with videos related to

Pageof 22
Sort By:
European Urology|January 14, 2014
A feasible and time-efficient adaptation of NeuroSAFE for da Vinci robot-assisted radical prostatectomyBurkhard Beyer, Thorsten Schlomm, Pierre Tennstedt, et al.
The Journal of Urology|February 8, 2002
Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomyMarkus Graefen, Pierre I Karakiewicz, Ilias Cagiannos, et al.
International Journal of Oncology|September 30, 2011
The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkersPierre Tennstedt, Patricia Köster, Andreas Brüchmann, et al.
The Journal of Urology|April 27, 2019
Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate BiopsyAlexander Haese, Geert Trooskens, Sandra Steyaert, et al.
Urology|September 7, 2012
Assessment of rates of lymph nodes and lymph node metastases in periprostatic fat pads in a consecutive cohort treated with retropubic radical prostatectomyJens Hansen, Lars Budäus, Jan Spethmann, et al.
The Journal of Urology|February 16, 2005
Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason gradeAlexander Haese, Ville Vaisanen, Hans Lilja, et al.
European Journal of Cancer (Oxford, England : 1990)|December 5, 2006
Body mass index does not improve the ability to predict biochemical recurrence after radical prostatectomyFelix K H Chun, Alberto Briganti, Markus Graefen, et al.
Urology|August 27, 2021
Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate VolumeEmily A Vertosick, Stephen Zappala, Sanoj Punnen, et al.
The Journal of Sexual Medicine|January 16, 2009
Importance of baseline potency rate assessment of men diagnosed with clinically localized prostate cancer prior to radical prostatectomyGeorg Salomon, Hendrik Isbarn, Lars Budaeus, et al.
Cancer|September 16, 2008
Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic featuresNazareno Suardi, Umberto Capitanio, Felix K H Chun, et al.
Pageof 22

Showing results (61-70 of 214) with videos related to

Sort By:
Pageof 22
European Urology|January 14, 2014
A feasible and time-efficient adaptation of NeuroSAFE for da Vinci robot-assisted radical prostatectomyBurkhard Beyer, Thorsten Schlomm, Pierre Tennstedt, et al.
The Journal of Urology|February 8, 2002
Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomyMarkus Graefen, Pierre I Karakiewicz, Ilias Cagiannos, et al.
International Journal of Oncology|September 30, 2011
The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkersPierre Tennstedt, Patricia Köster, Andreas Brüchmann, et al.
The Journal of Urology|April 27, 2019
Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate BiopsyAlexander Haese, Geert Trooskens, Sandra Steyaert, et al.
Urology|September 7, 2012
Assessment of rates of lymph nodes and lymph node metastases in periprostatic fat pads in a consecutive cohort treated with retropubic radical prostatectomyJens Hansen, Lars Budäus, Jan Spethmann, et al.
The Journal of Urology|February 16, 2005
Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason gradeAlexander Haese, Ville Vaisanen, Hans Lilja, et al.
European Journal of Cancer (Oxford, England : 1990)|December 5, 2006
Body mass index does not improve the ability to predict biochemical recurrence after radical prostatectomyFelix K H Chun, Alberto Briganti, Markus Graefen, et al.
Urology|August 27, 2021
Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate VolumeEmily A Vertosick, Stephen Zappala, Sanoj Punnen, et al.
The Journal of Sexual Medicine|January 16, 2009
Importance of baseline potency rate assessment of men diagnosed with clinically localized prostate cancer prior to radical prostatectomyGeorg Salomon, Hendrik Isbarn, Lars Budaeus, et al.
Cancer|September 16, 2008
Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic featuresNazareno Suardi, Umberto Capitanio, Felix K H Chun, et al.
Pageof 22